Introduction {#section1-2333794X17736700}
============

A high risk of thyroid cancer (TC) in adult-onset systemic lupus erythematosus (SLE) has been reported,^[@bibr1-2333794X17736700],[@bibr2-2333794X17736700]^ though a multiple-site international SLE cohort study has provided different conclusions.^[@bibr3-2333794X17736700]^ TC incidence in SLE patients in Scandinavian countries has been reported to be 0.4 to 3.4 per 10^5^ subjects.^[@bibr4-2333794X17736700]^ We wished to ascertain the factors promoting TC in childhood-onset SLE. To achieve this goal, symptoms, laboratory findings, medication, and complications were compared between TC-positive and TC-negative patients.

Methods {#section2-2333794X17736700}
=======

Ethical Approval of the Study Protocol {#section3-2333794X17736700}
--------------------------------------

The study protocol was approved by the Ethics Committee of Saitama Children's Medical Center (Saitama, Japan; Approval Number 16).

Participants {#section4-2333794X17736700}
------------

Fifty-three patients with a clinical diagnosis of SLE, mixed connective-tissue disease (MCTD), juvenile dermatomyositis/polymyositis (DM/PM), Sjögren's syndrome, and antisynthetase syndrome at our hospital between July and December 2014 were enrolled. Participant profiles are shown in [Table 1](#table1-2333794X17736700){ref-type="table"}. Diagnoses of SLE, MCTD, DM/PM, Sjögren's syndrome, and antisynthetase syndrome are described elsewhere.^[@bibr5-2333794X17736700][@bibr6-2333794X17736700][@bibr7-2333794X17736700][@bibr8-2333794X17736700]-[@bibr9-2333794X17736700]^ Remarkably, despite careful examination, TC was observed only in patients with SLE and not in patients with other collagen-based diseases.

###### 

Patients' Profile.

![](10.1177_2333794X17736700-table1)

  Disease                   Patients (Male--Female)   Age of Onset, Range (Median)   Current Age, Range (Median)
  ------------------------- ------------------------- ------------------------------ -----------------------------
  SLE                       29 (4:25)                 1-14 (12)                      13-30 (19)
  MCTD                      7 (0:7)                   2-12 (8)                       11-36 (16)
  DM/PM                     11 (2:9)                  3-14 (6)                       6-26 (16)
  Sjögren's syndrome        4 (2:2)                   4-12 (10)                      14-22 (16)
  Antisynthetase syndrome   2 (1:1)                   3-5 (4)                        10-20 (15)
  Total                     53 (9:44)                 1-14 (11)                      6-36 (17)

Abbreviations: SLE, systemic lupus erythematosus; MCTD, mixed connective tissue disease; DM/PM, dermatomyositis/polymyositis.

Examination Items {#section5-2333794X17736700}
-----------------

Medical records of 53 patients were investigated retrospectively. These items were derived from the diagnostic criteria^[@bibr9-2333794X17736700]^ and severity score^[@bibr10-2333794X17736700]^ of SLE.

### Symptoms at the Start of Treatment and During the Entire Study Period {#section6-2333794X17736700}

The cutaneous and mucosal symptoms that we examined were "butterfly rash," discoid lupus-like plaques, photosensitivity, painless ulcers (oral, nasal, or mucosal), hair loss, Reynaud's phenomenon, peptic ulcers, as well as other cutaneous and mucosal conditions.

### Neurological Symptoms {#section7-2333794X17736700}

The neurological symptoms that we examined were convulsions, psychological symptoms, organic brain syndrome, cranial-nerve symptoms, mononeuritis multiplex, disturbance of consciousness, cerebrovascular disorders, spinal disorders, aseptic meningitis, as well as other neurological symptoms.

### Musculoskeletal Symptoms {#section8-2333794X17736700}

The musculoskeletal symptoms that we examined were nondestructive arthritis (more than one), muscle pain, and muscle weakness.

### Cardiopulmonary Symptoms {#section9-2333794X17736700}

The cardiopulmonary symptoms that we examined were pleurisy, epicarditis, interstitial pneumonia, pulmonary hypertension, pulmonary infarction, pulmonary hemorrhage, as well as other cardiopulmonary symptoms.

### Renal Symptoms {#section10-2333794X17736700}

The renal symptoms that we examined were rapidly progressive nephritis, renal failure (acute and chronic), nephrotic syndrome, abnormal renal biopsy, as well as other renal symptoms.

### Systemic Symptoms {#section11-2333794X17736700}

The systemic symptoms that we examined were fever, weight loss, lymphadenopathy, splenomegaly, easy fatigability/general malaise/weakness, and loss of appetite/nausea/vomiting.

Laboratory Data at Treatment Start and Currently {#section12-2333794X17736700}
------------------------------------------------

An array of laboratory data were examined: white blood cells, lymphocytes, hemoglobin, platelets, creatinine, CH50, C3, C4, C-reactive protein (CRP), serum amyloid A (SAA), erythrocyte sedimentation rate (ESR), anti-nuclear antibody (ANA; homogeneous, speckled, nucleolar, peripheral, centromere, granular, and nuclear-membrane types), anti-DNA antibody, anti-double-stranded DNA (dsDNA) IgG, anti-Smith (Sm) antibody, anti-U1 ribonucleoprotein (U1RNP) antibody, anti-Sjögren's-syndrome-related antigen A (SSA) antibody, anti-Sjögren's-syndrome-related antigen B (SSB) antibody, anti-cardiolipin antibody, lupus anti-coagulant, biological false-positive (BFP), hemolytic anemia, proteinuria, hematuria, urinary granular casts, thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), thyroglobulin, anti-thyroglobulin antibody, anti-thyroid peroxidase (TPO) antibody, and thyroid-stimulating hormone receptor (TSHR) antibody.

Therapy {#section13-2333794X17736700}
-------

Prednisolone was excluded from the present study because all patients received this agent. The drugs that we evaluated were mycophenolate mofetil (MMF), methyl prednisolone (mPSL) pulse therapy, azathioprine (AZA), cyclosporine A (CyA), cyclophosphamide (CYP) pulse therapy, mizoribine, methotrexate (MTX), intravenous immunoglobulin (IVIG), tacrolimus, etanercept, and adalimumab.

Current Therapy and Its Effect {#section14-2333794X17736700}
------------------------------

We examined the effects of PSL, nonsteroidal anti-inflammatory drugs, immunosuppressive agents, mPSL pulse therapy, and CYP therapy, as well as other drugs.

Complications {#section15-2333794X17736700}
-------------

The complications that we looked for specifically were infection, peptic ulcers, diabetes mellitus, hypertension, compression fractures, osteonecrosis, cerebral infarction, myocardial infarction, disseminated intravascular coagulation, as well as other types of complications.

Statistical Analyses {#section16-2333794X17736700}
--------------------

In the whole analysis, the item "other" (eg, other skin conditions) was excluded from final data unless more than one patient exhibited the same attribute. Patient findings contributing to TC development were compared using the χ^2^ test and Fisher's exact test or nonparametric Mann-Whitney test. *P* values were 2-sided, and a significance of .05 was used. Statistical analyses were undertaken with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (R Foundation for Statistical Computing, Vienna, Austria).^[@bibr11-2333794X17736700]^

Methodological Quality {#section17-2333794X17736700}
----------------------

For methodological quality assessment, the checklist set by the Strengthening the Reporting of Observational Studies in Epidemiology^[@bibr12-2333794X17736700]^ and MOOSE guidelines^[@bibr13-2333794X17736700]^ were used.

Results {#section18-2333794X17736700}
=======

Case 1 {#section19-2333794X17736700}
------

A 24-year-old woman was diagnosed with SLE at the age of 14 years based on fever, butterfly rash, joint pain, swelling of lymph nodes in the neck, reduced numbers of blood cells, anti-nuclear antibody, anti-ds-DNA IgG antibody, anti-DNA antibody, and complement depletion. Renal biopsy was classified as IIIa.

She was treated with PSL, mPSL pulse therapy, AZA, and MMF. When she was 22 years old, she noticed swelling of the thyroid gland. She was diagnosed with papillary TC on ultrasonography. Tumor dimensions were 27 × 19 × 15 mm. After resection of the right lobe of the thyroid gland and dissection of paratracheal lymph nodes, TC did not relapse.

Case 2 {#section20-2333794X17736700}
------

Case 2 was a 22-year-old woman. At the age of 12 years, swelling of cervical lymph nodes, fever, erythema, hematuria, anti-ds-DNA IgG antibody, and hypocomplementemia led to the diagnosis of SLE. Renal biopsy was classified as IIIa.

She underwent treatment with PSL, mPSL pulse therapy, and MMF. She was rehospitalized because of relapse of enteropathy at the age of 20 years, and evaluation of the thyroid gland by ultrasound revealed TC. She was diagnosed with papillary TC and tumor dimensions were 9.8 × 9.5 × 15.7 mm. Resection of the right lobe of the thyroid gland, as well as dissection of paratracheal and peribronchial lymph nodes, was successful. Enteropathy was controlled by a combination of mPSL pulse therapy and AZA.

Case 3 {#section21-2333794X17736700}
------

Case 3 was a 14-year-old girl. When aged 14 years, she was diagnosed with SLE based on fever, butterfly rash, joint pain, anti-nuclear antibody, and cytopenia. She received PSL and mPSL pulse therapy. Thereafter, she developed lupus enteritis and was treated further with MMF. She was prescribed with mPSL pulse therapy, cyclosporine, and cyclophosphamide, but noticed a neck tumor 6 months after SLE onset. Ultrasound examination identified a tumor with intra-thyroid calcification. She was diagnosed with papillary TC, and tumor dimensions were 26 × 19 × 39 mm. Concomitant with thyroidectomy, neck lesions equivalent to TC tissue were identified and resected. Postoperatively, she has been treated with PSL without TC relapse.

TC Prevalence Among Patients With Rheumatic Disease {#section22-2333794X17736700}
---------------------------------------------------

TC was identified exclusively in patients with SLE, but not in those with other rheumatic diseases ([Table 2](#table2-2333794X17736700){ref-type="table"}). However, TC prevalence was not increased compared with that for other diseases.

###### 

Incidence of Thyroid Cancer in Patients With Rheumatic Diseases^[a](#table-fn3-2333794X17736700){ref-type="table-fn"}^.

![](10.1177_2333794X17736700-table2)

                            Thyroid Cancer (−)   Thyroid Cancer (+)   Sum
  ------------------------- -------------------- -------------------- -----
  SLE                       26                   3                    29
  MCTD                      7                    0                    7
  DM/PM                     11                   0                    11
  Sjögren's syndrome        4                    0                    4
  Antisynthetase syndrome   2                    0                    2
  Total                     50                   3                    53

Abbreviations: SLE, systemic lupus erythematosus; MCTD, mixed connective tissue disease; DM/PM, dermatomyositis/polymyositis.

*P* = .68.

Risk Factors in Patients With Rheumatic Disease {#section23-2333794X17736700}
-----------------------------------------------

### Demographic Features {#section24-2333794X17736700}

No items distinguished cancer-positive patients from cancer-free cases.

### Symptoms {#section25-2333794X17736700}

Lymphadenopathy/splenomegaly at the start of treatment and symptoms present during the entire period, such as lymphadenopathy/splenomegaly, painless ulcers (oral, nasal, mucosal), and weight loss, were precipitating factors for TC development ([Table 3](#table3-2333794X17736700){ref-type="table"}).

###### 

Risk Factors for the Development of Thyroid Cancer in Patients With Rheumatic Diseases.

\(1\) Demographic Features.

![](10.1177_2333794X17736700-table3)

                   Thyroid Cancer (−)   Thyroid Cancer (+)   *P*
  ---------------- -------------------- -------------------- ------
  Age              18.0                 20.3                 .478
  Age of onset     10.3                 9.3                  .692
  Family history   7/50                 0/3                  .952
  Sex, male (%)    0.22                 0                    1

###### 

\(2\) Clinical Symptoms.

![](10.1177_2333794X17736700-table4)

                                                 At the Start of Treatment   Entire Period                        
  ---------------------------------------------- --------------------------- --------------- ------ ------- ----- ------
  Butterfly rash                                 29/50                       2/3             1      31/50   3/3   .242
  Discoid papulosis                              2/50                        0/3             1      2/50    0/3   1
  Photosensitivity                               7/50                        0/3             1      7/50    0/3   1
  Oral, nasal, or mucosal painless ulcer         8/50                        2/3             .088   10/50   3/3   .012
  Hair loss                                      3/50                        0/3             1      6/50    1/3   .352
  Raynaud's phenomenon                           7/50                        0/3             1      11/50   0/3   1
  Peptic ulcer                                   0/50                        0/3             1      10/50   0/3   1
  Other skin conditions                          5/50                        2/3             .043   4/50    2/3   .031
  Convulsion                                     0/50                        0/3             1      2/50    0/3   1
  Psychological symptom                          2/50                        0/3             1      2/50    0/3   1
  Organic brain syndrome                         1/50                        0/3             1      0/50    0/3   1
  Cranial nerve symptoms                         0/50                        0/3             1      1/50    0/3   1
  Mononeuritis multiplex                         0/50                        0/3             1      0/50    0/3   1
  Disturbance of consciousness                   2/50                        0/3             1      4/50    0/3   1
  Cerebrovascular disorder                       0/50                        0/3             1      0/50    0/3   1
  Spinal disorder                                0/50                        0/3             1      0/50    0/3   1
  Aseptic meningitis                             0/50                        0/3             1      0/50    0/3   1
  Other neurological symptoms                    4/50                        0/3             1      4/50    0/3   1
  Nondestructive arthritis (more than two)       20/50                       2/3             .258   19/50   2/3   .555
  Muscle pain                                    3/50                        0/3             .567   15/50   0/3   .550
  Muscle weakness                                15/50                       0/3             .549   15/50   0/3   1
  Pleurisy                                       1/50                        0/3             1      2/50    0/3   1
  Epicarditis                                    2/50                        0/3             1      4/50    0/3   1
  Interstitial pneumonia                         1/50                        0/3             1      2/50    0/3   1
  Pulmonary hypertension                         2/50                        0/3             1      2/50    0/3   1
  Pulmonary infarction                           0/50                        0/3             1      0/50    0/3   1
  Pulmonary hemorrhage                           0/50                        0/3             1      0/50    0/3   1
  Other cardiopulmonary symptoms                 0/50                        0/3             1      0/50    0/3   1
  Rapidly progressive nephritis                  0/50                        0/3             1      0/50    0/3   1
  Acute renal failure                            0/50                        0/3             1      0/50    0/3   1
  Chronic renal failure                          0/50                        0/3             1      0/50    0/3   1
  Nephrotic syndrome                             0/50                        0/3             1      0/50    0/3   1
  Renal biopsy abnormal                          5/6                         2/2             1      8/12    2/3   1
  Other renal symptoms                           2/50                        0/3             1      1/50    0/3   1
  Fever                                          30/50                       3/3             .282   30/50   3/3   .282
  Weight loss                                    13/50                       1/3             1      13/50   3/3   .024
  Lymphadenopathy, splenomegaly                  11/50                       3/3             .016   11/50   3/3   .016
  Easy fatigability, general malaise, weakness   23/50                       2/3             .597   24/50   2/3   .611
  Loss of appetite, nausea, and vomiting         20/50                       2/3             .258   20/50   3/3   .076

###### 

\(3\) Laboratory Data.

![](10.1177_2333794X17736700-table5)

                           At the Start of Treatment   Current                           
  ------------------------ --------------------------- --------- ------- ------- ------- -------
  WBC (/µL)                5392                        4433      .686    5957    5766    .954
  Lymphocytes (/µL)        1456                        648       .084    1402    1339    .686
  Hb (g/dL)                117                         10.4      .143    12.9    10.6    .0393
  Plt (×10^4^/µL)          23.3                        22.4      1       27.2    30.7    .366
  Cre (mg/dL)              0.42                        0.55      .0706   0.54    0.48    .289
  CH50 (U/mL)              32.6                        7.0       .211    36.3    38.8    1
  C3 (mg/dL)               64.2                        60.0      .186    90.7    86      .677
  C4 (mg/dL)               11.4                        11.0      .367    19.2    20.3    .531
  CRP (mg/dL)              0.975                       0.563     .335    0.109   0.423   .341
  SAA (µg/mL)              167.5                       226.4     .127    10.15   28.67   .114
  ESR (mm/h)               47.1                        68.0      .193    16.42   23      .901
  ANA (fold)               1647                        1493      .658    605     40      .524
  Homogeneous type         22/43                       1/3       1       10/26   1/1     .407
  Speckled type            29/44                       2/3       1       14/26   1/1     1
  Nucleolar type           1/42                        0/3       1       0/26    0/1     1
  Peripheral type          1/42                        0/3       1       0/26    0/1     1
  Centromere type          0/42                        0/3       1       0/26    0/1     1
  Granular type            0/42                        0/3       1       1/26    0/1     1
  Nuclearmembrane type     0/42                        0/3       1       0/26    0/1     1
  Anti-DNA Ab (IU/mL)      88.3                        135.6     .374    8.35    6.33    .569
  Anti-dsDNA IgG (IU/mL)   126.5                       183.5     .55     6.84    6.07    .547
  Anti-Sm Ab               18/39                       2/2       .232    12/24   0/3     .537
  Anti-U1RNP Ab            18/36                       2/2       1       8/32    0/3     1
  Anti-SSA Ab              23/42                       1/3       .591    20/37   1/3     .596
  Anti-SSB Ab              12/41                       1/3       1       11/37   0/3     .548
  Anti-cardiolipin Ab      13/35                       2/3       .050    3/15    2/2     .132
  Lupus anticoagulant      8/34                        0/3       1       4/16    0/1     1
  BFP                      0/5                         0/1       1       0/2     0/0     1
  Hemolytic anemia         1/45                        0/2       1       0/47    0/3     1
  Proteinuria (mg/dL)      10.4                        22.0      .103    5.20    11.8    .483
  Hematuria                5/43                        1/3       .056    1/50    0/3     1
  Urine granular cast      1/43                        2/3       .127    1/50    0/3     1

Abbreviations: WBC, white blood cells; Hb, hemoglobin; Plt, platelet; Cre, creatinine; CH50, 50% hemolytic complement; C3, complement component 3; C4, complement component 4; CRP, C-reactive protein; SAA, serum amyloid A; ESR, erythrocyte sedimentation rate; ANA, anti-nuclear antibody; Ab, antibody; BFP, biological false positive.

###### 

\(4\) Therapy.

![](10.1177_2333794X17736700-table6)

               Thyroid Cancer (−)   Thyroid Cancer (+)   *P*
  ------------ -------------------- -------------------- ------
  MMF          36/50                3/3                  .557
  mPSL pulse   17/50                3/3                  .049
  AZA          17/50                2/3                  .290
  CyA          9/50                 1/3                  .920
  CYP pulse    4/50                 1/3                  .261
  Mizoribine   14/50                0/3                  .557
  MTX          11/50                0/3                  1
  IVIG         4/50                 0/3                  1
  Tacrolimus   2/50                 0/3                  1
  Eterercept   1/50                 0/3                  1
  Adalimab     1/50                 0/3                  1

Abbreviations: MMF, mycophenolate mofetil; mPSL, methyl prednisolone; AZA, azathioprine; CyA, cyclosporine A; CYP, cyclophosphamide; MTX, methotrexate; IVIG, intravenous immunoglobulin.

###### 

\(5\) Current Therapy and Its Effect.

![](10.1177_2333794X17736700-table7)

                        Current Therapy   Therapeutic Effect                        
  --------------------- ----------------- -------------------- ------ ------- ----- ------
  PSL                   44/50             3/3                  1      44/44   3/3   1
  NSAID                 10/50             0/3                  1      8/10    0/0   1
  Immunosuppressants    45/50             2/3                  .308   42/42   2/2   1
  mPSL pulse            1/50              0/3                  1      1/1     0/0   1
  CYP pulse             1/50              0/3                  1      1/1     0/0   1
  Others                11/50             2/3                  .145   10/11   1/1   .289
  Maximal dose of PSL   9.41              10.17                .327                 

Abbreviations: PSL, prednisolone; NSAID, nonsteroidal anti-inflammatory drug; mPSL, methyl prednisolone; CYP, cyclophosphamide.

###### 

\(6\) Complications.

![](10.1177_2333794X17736700-table8)

                          Thyroid Cancer (−)   Thyroid Cancer (+)   *P*
  ----------------------- -------------------- -------------------- ------
  Infection               9/50                 2/3                  .105
  Peptic ulcer            3/50                 0/3                  1
  Diabetes mellitus       1/50                 0/3                  1
  Hypertension            4/50                 0/3                  1
  Compression fracture    3/50                 0/3                  1
  Osteonecrosis           2/50                 1/3                  .163
  Cerebral infarction     0/50                 0/3                  1
  Myocardial infarction   0/50                 0/3                  1
  DIC                     0/50                 0/3                  1
  Others                  11/50                1/3                  .545

Abbreviations: DIC, disseminated intravascular coagulation.

### Laboratory Data {#section26-2333794X17736700}

Current hemoglobin levels in cancer patients were significantly lower (*P* = .0393) than in those who did not have cancer.

### Medication {#section27-2333794X17736700}

More patients with cancer received mPSL pulse therapy than those who did not have cancer.

### Current Therapy and Its Effect {#section28-2333794X17736700}

No mediations used in current therapy or their effect had an impact on TC development.

### Complications {#section29-2333794X17736700}

Prevalence of complications between the 2 groups was not different.

Risk Factors in SLE Patients {#section30-2333794X17736700}
----------------------------

### Demographic Factors {#section31-2333794X17736700}

None of the elements noted in SLE patients favored TC development ([Table 4](#table9-2333794X17736700){ref-type="table"}).

###### 

Risk Factors for the Development of Thyroid Cancer in Patients With SLE.

\(1\) Demographic Features.

![](10.1177_2333794X17736700-table9)

                   Thyroid Cancer (−)   Thyroid Cancer (+)   *P*
  ---------------- -------------------- -------------------- ------
  Age              18.9                 20.3                 .617
  Age of onset     10.3                 9.3                  .692
  Family history   3/19                 0/2                  1
  Sex, male (%)    0.154                0                    1

###### 

\(2\) Clinical Symptoms.

![](10.1177_2333794X17736700-table10)

                                                 At the Start of Treatment   Entire Period                         
  ---------------------------------------------- --------------------------- --------------- ------- ------- ----- -------
  Butterfly rash                                 11/26                       1/3             1       16/26   3/3   .532
  Discoid papulosis                              1/26                        0/3             1       1/26    0/3   1
  Photosensitivity                               5/26                        0/3             1       5/26    0/3   1
  Oral, nasal, or mucosal painless ulcer         8/26                        2/3             .267    9/26    3/3   .062
  Hair loss                                      1/26                        0/3             1       4/26    1/3   .446
  Raynaud's phenomenon                           3/26                        0/3             1       4/26    0/3   1
  Peptic ulcer                                   0/26                        0/3             1       4/26    0/3   1
  Other skin conditions                          3/25                        2/3             .0733   1/25    2/3   .0232
  Convulsion                                     3/26                        0/3             1       3/26    0/3   1
  Psychological symptom                          3/26                        0/3             1       3/26    0/3   1
  Organic brain syndrome                         1/25                        0/3             1       1/25    0/3   1
  Cranial nerve symptoms                         1/25                        0/3             1       0/25    0/3   1
  Mononeuritis multiplex                         1/25                        0/3             1       0/25    0/3   1
  Disturbance of consciousness                   2/26                        0/3             1       2/26    0/3   1
  Cerebrovascular disorder                       0/26                        0/3             1       0/26    0/3   1
  Spinal disorder                                0/26                        0/3             1       0/26    0/3   1
  Aseptic meningitis                             0/26                        0/3             1       0/26    0/3   1
  Other neurological symptoms                    1/25                        0/3             1       2/25    0/3   1
  Nondestructive arthritis (more than two)       12/26                       2/3             .598    12/26   2/3   .598
  Muscle pain                                    2/26                        0/3             1       5/26    0/3   1
  Muscle weakness                                3/26                        0/3             1       3/26    0/3   1
  Pleurisy                                       0/26                        0/3             1       1/26    0/3   1
  Epicarditis                                    1/26                        0/3             1       3/26    0/3   1
  Interstitial pneumonia                         0/26                        0/3             1       1/26    0/3   1
  Pulmonary hypertension                         0/26                        0/3             1       0/26    0/3   1
  Pulmonary infarction                           0/26                        0/3             1       0/26    0/3   1
  Pulmonary hemorrhage                           0/26                        0/3             1       0/26    0/3   1
  Other cardiopulmonary symptoms                 0/25                        0/3             1       0/25    0/3   1
  Rapidly progressive nephritis                  0/26                        0/3             1       0/26    0/3   1
  Acute renal failure                            0/26                        0/3             1       0/26    0/3   1
  Chronic renal failure                          0/26                        0/3             1       0/26    0/3   1
  Nephrotic syndrome                             0/26                        0/3             1       0/26    0/3   1
  Renal biopsy abnormal                          5/7                         2/2             1       10/11   1/1   1
  Other renal symptoms                           1/25                        1/3             .206    2/26    0/3   1
  Fever                                          18/25                       3/3             .551    20/26   3/3   1
  Weight loss                                    6/26                        1/3             1       6/26    3/3   .023
  Lymphadenopathy, splenomegaly                  8/26                        3/3             .0452   8/26    3/3   .045
  Easy fatigability, general malaise, weakness   12/26                       2/3             .598    13/26   2/3   1
  Loss of appetite, nausea, and vomiting         12/26                       2/3             .598    12/26   3/3   .224

###### 

\(3\) Laboratory Data.

![](10.1177_2333794X17736700-table11)

                           At the Start of Treatment   Current                          
  ------------------------ --------------------------- --------- ------ ------- ------- -------
  WBC (/µL)                4276                        4433      .496   5413    5766    .474
  Lymphocytes (/µL)        1055                        648       .371   957     1339    .092
  Hb (g/dL)                11.1                        10.4      .333   12.8    10.6    .0341
  Plt (×10^4^/µL)          16.7                        22.4      .35    24      30.7    .112
  Cre (mg/dL)              0.47                        0.55      .266   1.41    0.48    .282
  CH50 (U/mL)              22.1                        7.0       .298   32.8    38.8    .618
  C3 (mg/dL)               64.2                        60.0      .616   84.2    86      .641
  C4 (mg/dL)               11.4                        11.0      .693   16.1    20.3    .37
  CRP (mg/dL)              0.975                       0.563     .519   0.098   0.423   .325
  SAA (µg/mL)              167.5                       226.4     .229   10.05   28.67   .146
  ESR (mm/h)               47.1                        68.0      .334   16.4    23      .926
  ANA (fold)               1647                        1493      .687   769     40      .243
  Homogeneous type         15/26                       1/3       .573   8/14    1/1     .243
  Speckled type            19/26                       2/3       1      12/14   1/1     1
  Nucleolar type           1/26                        0/3       1      0/14    0/1     1
  Peripheral type          0/26                        0/3       1      0/14    0/1     1
  Centromere type          0/26                        0/3       1      0/14    0/1     1
  Granular type            0/26                        0/3       1      1/14    0/1     1
  Nuclearmembrane type     0/26                        0/3       1      0/14    0/1     1
  Anti-DNA Ab (IU/mL)      88.3                        135.6     .709   10.23   6.33    .367
  Anti-dsDNA IgG (IU/mL)   126.5                       183.5     .876   8.73    6.07    .316
  Anti-Sm Ab               15/22                       2/3       1      6/22    0/3     .554
  Anti-U1RNP Ab            6/18                        2/3       1      2/20    0/3     1
  Anti-SSA Ab              19/24                       1/3       .156   17/23   1/3     .215
  Anti-SSB Ab              8/23                        1/3       1      6/23    0/3     1
  Anti-cardiolipin Ab      13/22                       2/3       1      3/13    2/2     .095
  Lupus anti-coagulant     7/21                        0/3       .53    3/12    0/1     1
  BFP                      0/4                         0/1       1      0/0     0/0     1
  Hemolytic anemia         1/25                        0/3       1      0/26    0/3     .316
  Proteinuria (mg/dL)      111                         22.0      .139   3.14    11.8    .187
  Hematuria                5/25                        2/3       .145   1/25    0/3     1
  Urine granular cast      1/25                        2/3       .023   1/25    0/3     1

Abbreviations: WBC, white blood cells; Hb, hemoglobin; Plt, platelet; Cre, creatinine; CH50, 50% hemolytic complement; C3, complement component 3; C4, complement component 4; CRP, C-reactive protein; SAA, serum amyloid A; ESR, erythrocyte sedimentation rate; ANA, anti-nuclear antibody; Ab, antibody; BFP, biological false positive.

###### 

\(4\) Therapy.

![](10.1177_2333794X17736700-table12)

               Thyroid Cancer (−)   Thyroid Cancer (+)   *P*
  ------------ -------------------- -------------------- ------
  MMF          21/26                3/3                  1
  mPSL pulse   9/26                 3/3                  .060
  AZA          12/26                2/3                  .598
  CyA          1/26                 1/3                  .200
  CYP pulse    2/26                 1/3                  .298
  Mizoribine   10/26                0/3                  .532
  MTX          2/26                 0/3                  1
  IVIG         2/26                 0/3                  1
  Tacrolimus   2.26                 0/3                  1
  Eterercept   0/26                 0/3                  1
  Adalimab     0/26                 0/3                  1

Abbreviations: MMF, mycophenolate mofetil; mPSL, methyl prednisolone; AZA, azathioprine; CyA, cyclosporine A; CYP, cyclophosphamide; MTX, methotrexate; IVIG, intravenous immunoglobulin.

###### 

\(5\) Current Therapy and Its Effect.

![](10.1177_2333794X17736700-table13)

                        Current Therapy   Therapeutic Effect                        
  --------------------- ----------------- -------------------- ------ ------- ----- ------
  PSL                   26/26             3/3                  1      26/26   3/3   .237
  NSAID                 6/24              0/3                  1      5/6     0/0   1
  Immunosuppressants    25/26             2/3                  .2     25/25   2/2   .2
  mPSL pulse            0/25              0/3                  1                    
  CYP pulse             0/25              0/3                  1                    
  Others                0/20              0/2                  1      5/6     0/0   1
  Maximal dose of PSL   6.63              10.17                .237                 

Abbreviations: PSL, prednisolone; NSAID, nonsteroidal anti-inflammatory drug; mPSL, methyl prednisolone; CYP, cyclophosphamide.

###### 

\(6\) Complications.

![](10.1177_2333794X17736700-table14)

                          Thyroid Cancer (−)   Thyroid Cancer (+)   *P*
  ----------------------- -------------------- -------------------- ------
  Infection               7/25                 2/3                  .234
  Peptic ulcer            0/25                 0/3                  1
  Diabetes mellitus       0/26                 0/3                  1
  Hypertension            3/25                 0/3                  1
  Compression fracture    2/25                 0/3                  1
  Osteonecrosis           2/25                 1/3                  .293
  Cerebral infarction     0/25                 0/3                  1
  Myocardial infarction   0/25                 0/3                  1
  DIC                     0/25                 0/3                  1
  Others                  4/26                 1/3                  .446

Abbreviation: DIC, disseminated intravascular coagulation.

### Symptoms {#section32-2333794X17736700}

Lymphadenopathy/splenomegaly at treatment commencement and lymphadenopathy/splenomegaly and weight loss during the entire period promoted TC development in SLE patients.

### Laboratory Data {#section33-2333794X17736700}

Urinary granular casts at the start of therapy and currently low hemoglobin levels were contributing factors to TC development.

### Medications {#section34-2333794X17736700}

Specific examination for SLE revealed no significant differences between patients with or without TC ([Table 4](#table9-2333794X17736700){ref-type="table"}).

### Current Therapy and Its Effect {#section35-2333794X17736700}

We did not find any items that increase the risk of TC with regard to current treatment and its effect.

### Complications {#section36-2333794X17736700}

Definite comorbidities that differentiate cancer patients from noncancer patients were not identified.

Thyroid Hormone and Autoantibodies {#section37-2333794X17736700}
----------------------------------

Levels of thyroid hormones (TSH, FT3, FT4) in TC patients were not different from those of cancer-free patients with regard to rheumatic diseases or specifically to SLE ([Table 5](#table15-2333794X17736700){ref-type="table"}). Levels of thyroglobulin and autoantibodies (eg, anti-thyroglobulin, anti-TPO, TSHR antibody) in rheumatic disease and SLE were not significantly different ([Table 5](#table15-2333794X17736700){ref-type="table"}).

###### 

Thyroid Hormone and Autoantibodies.

\(1\) Rheumatic Diseases.

![](10.1177_2333794X17736700-table15)

                               Thyroid cancer (−), Mean ± SD   Thyroid Cancer (+), Mean ± SD   *P*
  ---------------------------- ------------------------------- ------------------------------- ------
  TSH (µU/mL)                  1.38 ± 1.05                     1.30 ± 0.26                     .908
  FT3 (pg/mL)                  2.71 ± 0.69                     2.50 ± 0.53                     .608
  FT4 (ng/dL)                  1.11 ± 0.17                     1.01 ± 0.12                     .306
  Thyroglobulin (ng/mL)        19.16 ± 12.70                   13.53 ± 13.04                   .465
  Anti-thyroglobulin (IU/mL)   16.05 ± 16.81                   12.33 ± 2.08                    .707
  Anti-TPO (IU/mL)             10.66 ± 8.40                    10.66 ± 7.37                    .998
  TSHR antibody (IU/L)         1.43 ± 7.69                     0.50 ± 0.00                     .783

Abbreviations: TSH, thyroid-stimulating hormone; FT3, free triiodothyronine; FT4, free thyroxine; TPO, thyroid peroxidase; TSHR, thyroid-stimulating hormone receptor.

###### 

\(2\) Systemic Lupus Erythematosus.

![](10.1177_2333794X17736700-table16)

                               Thyroid cancer (−), Mean ± SD   Thyroid cancer (+), Mean ± SD   *P*
  ---------------------------- ------------------------------- ------------------------------- ------
  TSH (µU/mL)                  1.38 ± 0.86                     1.30 ± 0.26                     .869
  FT3 (pg/mL)                  2.67 ± 0.78                     2.50 ± 0.53                     .720
  FT4 (ng/dL)                  1.11 ± 0.17                     1.01 ± 0.12                     .345
  Thyroglobulin (ng/mL)        19.44 ± 13.35                   13.53 ± 13.04                   .480
  Anti-thyroglobulin (IU/mL)   14.82 ± 10.07                   12.33 ± 2.08                    .679
  Anti-TPO (IU/mL)             10.87 ± 9.85                    10.66 ± 7.37                    .973
  TSHR antibody (IU/L)         2.07 ± 6.18                     0.50 ± 0.00                     .730

Abbreviations: TSH, thyroid-stimulating hormone; FT3, free triiodothyronine; FT4, free thyroxine; TPO, thyroid peroxidase; TSHR, thyroid-stimulating hormone receptor.

Discussion {#section38-2333794X17736700}
==========

Similar to the report that identified AZA as a risk factor for thyroid nodules in SLE,^[@bibr14-2333794X17736700]^ we identified several risk factors that may lead to TC development. Expression of each factor may suggest that TC patients have high SLE activity because these items are associated with severe disease.^[@bibr10-2333794X17736700]^ Furthermore, mPSL pulse therapy is ubiquitous for rheumatic diseases (mainly targeting severe disease) and may contribute to the relatively high distribution among TC patients, with low distribution among cancer-free patients with rheumatic disease. We identified lymphadenopathy/splenomegaly and weight loss to be risk factors, which are systemic conditions (and not organ-specific symptoms) as defined by the severity index.^[@bibr10-2333794X17736700]^ Owing to the small sample size, rheumatic diseases as a whole were associated with more risk factors than SLE alone as a specific single disease entity.

In our investigation, thyroid immunity and thyroid hormones were compared between cancer-positive and cancer-free patients because involvement of the autoimmunity and function of the thyroid gland in cancer development has been suggested by Antonelli et al^[@bibr1-2333794X17736700]^ and Papendieck et al.^[@bibr15-2333794X17736700]^ Our data were not in accordance with their results, and we did not find a distinction in autoantibody levels or hormone levels in the thyroid gland.

With the development of medical technology, identification of thyroid tumors (including benign nodules) has become more common, and some authors recognize benign tumors as "thyroid incidentalomas."^[@bibr16-2333794X17736700]^ However, Papendieck et al suggested a higher prevalence of TC in pediatric thyroid nodules than in adult thyroid nodules.^[@bibr15-2333794X17736700]^ Therefore, we advocate careful investigations to find occult thyroid cancers because failure to detect "true" malignant tumors of the thyroid gland may result in a poor prognosis for SLE patients who carry the potential risk factors to develop them.

Our study had limitations. We evaluated a small number of SLE patients and those with other rheumatic diseases. Using Yates' correction, we analyzed small-sample data in the χ^2^ test. Moreover, we used univariate analyses instead of multivariate analyses because an extremely low prevalence of TC did not permit enrolment of sufficient numbers of affected patients (which did not allow for analyses of the confounders that favor TC development). To use logistic regression analyses to study as few as 2 confounders, ≥20 cancer-positive SLE patients are required, which corresponds to ≈200 000 cancer-free SLE patients. Understandably, further expansion of confounders requires large populations.

Conclusion {#section39-2333794X17736700}
==========

There are several risk factors for TC development in pediatric SLE. Efforts should be made to find thyroid tumors carefully and intensively and to extract various characteristics among large numbers of TC-positive SLE children to permit multivariate analyses. Our results warrant a wide range of multicenter epidemiological studies instead of the single-center investigation described here.
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